Represented Prometheus Laboratories, Inc. owner of an Orange Book listed branded drug, Lotronex (alosetron hydrochloride), indicated for women with severe Irritable Bowel Syndrome. Prometheus Labs bought the franchise from GSK several years ago, however US Patent No. 6,284,770 drawn to a method for treatment was not listed in the Orange Book. A reexamination strategy was devised to ensure patentability of the claims that covered the indication. After an initial PTO action denying the reexamination request, a petition was filed citing further relevant facts. Thereafter, the petition was granted. After successful prosecution of amended claims, a reexamination certificate issued providing valid patent coverage for Lotronex. The reexamined patent is now listed in the Orange Book.